Boston Scientific (NYSE:BSX) vs. RxSight (NASDAQ:RXST) Head-To-Head Survey

Boston Scientific (NYSE:BSX) and RxSight (NASDAQ:RXST) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Insider and Institutional Ownership

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 0.3% of Boston Scientific shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Boston Scientific has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Profitability

This table compares Boston Scientific and RxSight’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Boston Scientific	16.62%	18.61%	10.58%
RxSight	-43.80%	-20.11%	-16.31%

Valuation and Earnings

This table compares Boston Scientific and RxSight”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07 billion	3.19	$2.90 billion	$2.36	18.74
RxSight	$134.48 million	1.68	-$38.94 million	($1.28)	-4.20

Boston Scientific has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Boston Scientific and RxSight, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2	8	20	1	2.65
RxSight	2	7	2	0	2.00

Boston Scientific currently has a consensus target price of $61.43, indicating a potential upside of 38.92%. RxSight has a consensus target price of $6.94, indicating a potential upside of 29.07%. Given Boston Scientific’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Boston Scientific is more favorable than RxSight.

Summary

Boston Scientific beats RxSight on 13 of the 15 factors compared between the two stocks.

About Boston Scientific

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

About RxSight

RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.